RxDoctor Payments DataLook up a doctor →

Melanie McGilloway, NP

Nurse Practitioner · San Diego, CANPI 1366921322

Payments from drug & device makers

$33,423in general payments, 2019–2025

Across 580 payments — averaging $57.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accord Healthcare, Inc.$12K
  • Johnson & Johnson$5K
  • Axonics, Inc.$2K
  • Dendreon Pharmaceuticals LLC$2K
  • Teleflex LLC$2K
  • Bayer$1K
  • plus $9K from 40 others

What the payments were for

  • Consulting fees$3,0509%
  • Speaking & faculty fees$3,86012%
  • Travel & lodging$5,19216%
  • Food & beverage$20,88262%
  • Education$4391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,423 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$46,921
Medicare patients
101
Services billed
2,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide86$1,236,727
XtandiEnzalutamide68$843,035
NubeqaDarolutamide32$429,996
OrgovyxRelugolix123$321,732
Abiraterone Acetate58$127,047
GemtesaVibegron74$59,863
MyrbetriqMirabegron52$44,658
XyostedTestosterone Enanthate11$6,863
Tamsulosin Hcl366$6,032
Estradiol64$4,136
Methenamine Hippurate31$2,801
Finasteride152$2,256
Testosterone13$1,903
Oxybutynin Chloride ErOxybutynin Chloride51$1,710
Potassium Citrate ErPotassium Citrate20$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$4,749$1,236,72786 claims
Astellas Pharma US IncXtandi, Myrbetriq$811$887,693120 claims
BayerNubeqa$1,134$429,99632 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$443$381,595197 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$588$127,04758 claims
Antares Pharma, Inc.Xyosted$247$6,86311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →